MedKoo Cat#: 414791 | Name: Parvaquone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Parvaquone is an Anti-Infective, Antiparasitic, and Antiprotozoal agent

Chemical Structure

Parvaquone
Parvaquone
CAS#4042-30-2

Theoretical Analysis

MedKoo Cat#: 414791

Name: Parvaquone

CAS#: 4042-30-2

Chemical Formula: C16H16O3

Exact Mass: 256.1099

Molecular Weight: 256.30

Elemental Analysis: C, 74.98; H, 6.29; O, 18.73

Price and Availability

Size Price Availability Quantity
5g USD 255.00 2 Weeks
10g USD 415.00 2 Weeks
25g USD 665.00 2 Weeks
50g USD 1,000.00 2 Weeks
100g USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Parvaquone; NSC278; NSC-278; NSC 278
IUPAC/Chemical Name
1,4-Naphthalenedione, 2-cyclohexyl-3-hydroxy-
InChi Key
JBFUOGRCSLVENL-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16O3/c17-14-11-8-4-5-9-12(11)15(18)16(19)13(14)10-6-2-1-3-7-10/h4-5,8-10,19H,1-3,6-7H2
SMILES Code
O=C1C(C2CCCCC2)=C(O)C(C3=C1C=CC=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 256.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hines SA, Brandvold J, Mealey RH, Call DR, Graça T. Exposure to ambient air causes degradation and decreased in vitro potency of buparvaquone and parvaquone. Vet Parasitol X. 2020 Feb 7;3:100023. doi: 10.1016/j.vpoa.2020.100023. PMID: 32904749; PMCID: PMC7458381. 2: Mbwambo HA, Sudi FF, Mkonyi PA, Mfinanga JM, Mella ES, Ngovi CJ. Comparative studies of the efficacy of parvaquone and parvaquone-plus-frusemide in the treatment of Theileria parva infection (East Coast fever) in cattle. Vet Parasitol. 2002 Sep 26;108(3):195-205. doi: 10.1016/s0304-4017(02)00195-4. PMID: 12237138. 3: Muraguri GR, Kiara HK, McHardy N. Treatment of East Coast fever: a comparison of parvaquone and buparvaquone. Vet Parasitol. 1999 Nov;87(1):25-37. doi: 10.1016/s0304-4017(99)00154-5. PMID: 10628697. 4: Musoke RA, Tweyongyere R, Bizimenyera E, Waiswa C, Mugisha A, Biryomumaisho S, McHardy N. Treatment of East Coast fever of cattle with a combination of parvaquone and frusemide. Trop Anim Health Prod. 2004 Apr;36(3):233-45. doi: 10.1023/b:trop.0000016832.69136.68. PMID: 15080540. 5: Hashemi-Fesharki R. Chemotherapeutic value of parvaquone and buparvaquone against Theileria annulata infection of cattle. Res Vet Sci. 1991 Mar;50(2):204-7. doi: 10.1016/0034-5288(91)90107-y. PMID: 2034901. 6: Dolan TT, Linyonyi A, Mbogo SK, Young AS. Comparison of long acting oxytetracycline and parvaquone in immunisation against East Coast fever by infection and treatment. Res Vet Sci. 1984 Sep;37(2):175-8. PMID: 6438743. 7: Bansal GC, Sharma SP. Efficacy of parvaquone and long-acting oxytetracycline in Theileria annulata infection. Vet Parasitol. 1986 Aug;21(3):145-9. doi: 10.1016/0304-4017(86)90061-0. PMID: 3750805. 8: Dolan TT, Young AS, Leitch BL, Stagg DA. Chemotherapy of East Coast fever: parvaquone treatment of clinical disease induced by isolates of Theileria parva. Vet Parasitol. 1984 Aug;15(2):103-16. doi: 10.1016/0304-4017(84)90026-8. PMID: 6437050. 9: Hines SA, Brandvold J, Mealey RH, Call DR, Graça T. Exposure to ambient air causes degradation and decreased in vitro potency of buparvaquone and parvaquone. Vet Parasitol. 2020;277S:100023. doi: 10.1016/j.vpoa.2020.100023. Epub 2020 Feb 7. PMID: 34392948. 10: Motzel SL, Wagner JE. Treatment of experimentally induced cytauxzoonosis in cats with parvaquone and buparvaquone. Vet Parasitol. 1990 Feb;35(1-2):131-8. doi: 10.1016/0304-4017(90)90122-r. PMID: 2111598.